[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institute of Cardiovascular Diseases, Vojvodina\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":72},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,45],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100573434","drug-eluting-balloon-or-drug-eluting-stent-in-acute-myocardial-infarction-a-randomized-controlled-trial-100573434",false,"NCT06746233","Drug-Eluting Balloon or Drug-Eluting Stent in Acute Myocardial Infarction: A Randomized Controlled Trial","A Prospective, Randomized, Multicenter, International, Open-Label Clinical Trial Comparing Drug-Coated Balloon and Drug-Eluting Stent for the Treatment of Acute ST-Elevation Myocardial Infarction.","BOOST-AMI","Inclusion Criteria:\n\n* Age \\>18 years with a life expectancy of \\>1 year;\n* Patients fulfilling criteria for STEMI (\\>20 min of chest-pain; At least 1 mm ST-elevation in at least two contiguous leads, a new left bundle branch block or a true posterior myocardial infarction confirmed by ECG or echocardiography; Reperfusion is expected to be feasible within 12 h after onset of symptoms)\n* Infarct related artery eligible for primary PCI (De novo lesion in a native coronary artery; Reference-vessel diameter ≥2.5 mm and ≤ 4 mm; Absence of severe calcification; Residual diameter stenosis of ≤30% (by visual assessment) after lesion preparation after lesion preparation; Absence of coronary dissection type ≥C.\n\nExclusion Criteria:\n\n* Killip class\\>II on admission\n* Known contraindication for aspirin, clopidogrel, ticagrelor, heparin or GP IIb\u002FIIIa inhibitor\n* Previous myocardial infarction\n* Previous PCI in the territory of the infarct-related artery (IRA)\n* Previous CABG\n* 3-vessel disease requiring revascularization\n* Left-main disease\n* Extremely angulated or severely calcified vessels\n* History of ischemic stroke within the past 6 months or hemorrhagic stroke\n* Planned CABG for a non-culprit vessel\n* Participation in another investigational trial that has not completed its primary endpoint or could interfere with the endpoints of this study","ALL","18 Years",{"count":20,"type":21},598,"ESTIMATED","INTERVENTIONAL",[24],"NA","The objective of the study is to compare drug-coated balloon (DCB) with the gold standard drug-eluting stent (DES) in percutaneous coronary intervention (PCI) for patients presenting with ST-elevation myocardial infarction (STEMI).\n\nRandomization will be performed after successful culprit-lesion preparation and confirmation that all angiographic entry criteria are met. Patients will be randomly assigned in a 1:1 fashion to receive either treatment with a Paclitaxel-coated balloon alone or second or third-generation DES.",[27],"ST Elevation Myocardial Infarction (STEMI)",[29,30,31],"STEMI","DES","DCB","RECRUITING","2026-03-25",{"date":35,"type":36},"2026-03-30","ACTUAL",{"date":38,"type":36},"2024-12-25",{"date":40,"type":21},"2028-12",{"name":42,"class":43},"Institute of Cardiovascular Diseases, Vojvodina","OTHER",5,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},"100620690","atrial-fibrillation-trial-of-left-atrial-appendage-closure-using-seralene-hemostatic-suture-100620690","NCT07360899","Atrial Fibrillation TRIal of Left Atrial Appendage Closure Using Seralene Hemostatic Suture","Left Atrial Appendage Closure During Cardiac Surgery in Atrial Fibrillation Patients With Seralene","ATRI-LASH","Inclusion Criteria:\n\nAge 18 years or older\n\nDocumented atrial fibrillation (any type)\n\nCHA₂DS₂-VASc score of 2 or greater, or equivalent stroke risk\n\nScheduled to undergo cardiac surgery (including coronary artery bypass grafting, valve surgery, or other structural cardiac surgery)\n\nAbility to understand the study and provide written informed consent\n\nExclusion Criteria:\n\nContraindication to left atrial appendage closure (e.g., presence of left atrial appendage thrombus or unsuitable anatomy)\n\nLife expectancy less than 3 months, based on clinical judgment\n\nCurrent participation in another clinical study that could interfere with the outcomes of this study\n\nActive or suspected infective endocarditis",{"count":54,"type":21},200,[24],"Atrial fibrillation is a common heart rhythm disorder that increases the risk of stroke. In patients with atrial fibrillation, blood clots most often form in a small structure of the heart called the left atrial appendage. If a blood clot travels from the heart to the brain, it can cause a stroke.\n\nBlood-thinning medications are commonly prescribed to reduce the risk of stroke in patients with atrial fibrillation. However, some patients cannot take these medications long-term because of bleeding risk, side effects, or other medical reasons.\n\nClosing the left atrial appendage is an alternative approach to reduce the risk of stroke by preventing blood from collecting in this area. When patients undergo cardiac surgery for another indication, closure of the left atrial appendage can be performed during the same operation.\n\nThis study is designed to evaluate the safety and effectiveness of surgical closure of the left atrial appendage using a device called AtriLASH during cardiac surgery. AtriLASH is a surgical suture-based device intended to close the left atrial appendage.\n\nThe study will assess whether the left atrial appendage can be safely and effectively closed using this method in patients with atrial fibrillation undergoing cardiac surgery. The information obtained from this study may help determine whether this approach can reduce the risk of stroke and potentially decrease the need for long-term use of blood-thinning medications in selected patients.",[58,59,60,61,62],"ATRIAL APPENDAGE CLOSURE for ATRIAL FIBRILLATION","Atrial Fibrillation (AF)","Mitral Valve Surgery","Stroke (in Patients With Atrial Fibrillation)","Anticoagulant Therapy","2026-01-14",{"date":65,"type":36},"2026-01-22",{"date":67,"type":36},"2025-12-01",{"date":69,"type":21},"2026-06-30",{"name":42,"class":43},1,""]